Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further ...

The category could also see competition from Ambrx – in the process of being acquired by Johnson & Johnson in a $2 billion deal - whose PSMA-targeting antibody-drug conjugate (ADC) ARX517 showed ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data from preclinical studies of three exatecan-based ...

It's worth noting that Bayer has its own PSMA-targeting thorium-227 drug – BAY 2315497 – in phase 1 development, which uses an antibody for tumour targeting. Its other clinical stage TAT (BAY ...

Nauseef JT, Sun MP, Thomas C, et al. A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer in patients with prior treatment with ...

To address these challenges, AbCellera developed a T-cell engager platform that includes novel CD3-binding antibodies to expand the therapeutic window for this modality and costimulatory building ...

Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate ... which is to combine diverse CD3- and tumor-binding antibodies and use empirical testing to engineer optimized ...

a novel PSMA-targeting ADC, were presented in a poster presentation titled, "Preclinical Development of ADCT-241, a Novel Exatecan-based Antibody-Drug Conjugate Targeting PSMA for the Treatment of ...

Preclinical data on AbCellera’s PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies ...